Autism Spectrum Disorder Trial, Recruiting NCT06466876 Sponsor: Louisiana State University and A&M College Condition: Autism Spectrum Disorder
Back to Autism Spectrum Disorder

Autism Spectrum Disorder Trial, Recruiting

NCT06466876
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Children between 4 and 10 years old who have already been diagnosed with autism spectrum disorder (ASD) in their community, and whose diagnosis is confirmed using a standard autism assessment tool called the ADOS-2.
  • Children who are able to speak in at least simple sentences on their own (not just when prompted), as the study involves learning and saying new words out loud.
  • Children whose main language spoken at home is English.
  • Children who pass a basic hearing screening at the start of the study.
  • Children who score above 75 on a nonverbal thinking and reasoning assessment called the Leiter-3, which measures cognitive ability without relying on language.

Who may not be able to join:

  • Children who are non-speaking or who are only able to speak very minimally, meaning they are not able to produce at least simple sentences on their own.
  • Children who have a history of a neurological condition (such as cerebral palsy) or a known genetic condition that causes developmental delays or disorders.
  • Children who have a hearing loss that has not been corrected (for example, with hearing aids or other treatment).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Eileen K Haebig, PhD, Louisiana State University Health Sciences Center in New Orleans

Phone: 225-578-3933

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Louisiana State University and A&M College
Registry
ClinicalTrials.gov
Start date
28 July 2023
Est. completion
30 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Word form recall; Word meaning recall; Form-referent-link recognition

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov